KAN.ST

Compare

No price history available for this symbol yet.

Fair-value model

Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.

Years of analysisAssumption entries

Analyst estimates unavailable for this ticker.

Held by

portfolios on TandT

Bookmarked by

users

Avg position size

—

of holders' portfolios

13F filers

institutions

Sector

Biotechnology

Analyst estimates (consensus)

Year	Est. revenue	Growth	Est. EPS	EPS range	Fwd P/E	# Analysts
2026	$20M	-94.0%	$0.00	$0.00–$0.00	—	0
2027	$140000	-99.3%	$0.00	$0.00–$0.00	—	0

Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep

Earnings surprises

Beat consensus in 3 of the last 6 reported quarters

Reported	Est. EPS	Actual	Surprise
2024-11-15	$0.46	$-0.09	-119.6%
2024-08-23	$-0.17	$-0.09	+47.1%
2024-05-17	$-0.20	$-0.13	+35.0%
2024-02-23	$-0.15	$-0.22	-51.1%
2023-11-17	$-0.21	$-0.13	+40.1%
2023-08-18	$-0.16	$-0.22	-41.5%

DCF fair valuemodel estimate

Intrinsic value

$0.40

Price

$0.30

Implied upside

+33%

Peer comparison

Symbol	Price	Today	Mkt cap	P/E
KAN.STKancera AB (publ)	$0.30	+0.00%	$36M	—
AMNI.STAmniotics AB (publ)	$0.01	+5.88%	$15M	—
COALA.STCoala-Life Group AB (publ)	$0.02	+5.49%	$25M	—
COMBI.STCombiGene AB (publ)	$2.47	-3.89%	$49M	—
DIABIO.STDiagonal Bio AB (publ)	$0.01

Kancera AB (publ)

Kancera AB (publ), a biopharmaceutical firm founded in Solna, Sweden, in 2010, specializes in the development of new treatments for inflammatory disorders and various types of cancer, operating both domestically and internationally. The company's pipeline includes several small molecule drug candidates. KAND567 is presently in a Phase IIa clinical trial, assessing its effectiveness against inflammatory heart disease occurring after a heart attack. Additionally, KAND145 is undergoing a Phase I study with healthy volunteers to establish optimal dosing for cancer therapy, alongside a Phase IIa study specifically targeting ovarian cancer. Kancera's research efforts also encompass HDAC inhibitors for managing nerve inflammation and pain, as well as ROR1 inhibitors for addressing solid tumors and blood-related cancers.

novakand.com

Employees: 5
IPO / List date: Feb 25, 2011
HQ: SE

Held by traders on TradeandTell

No one on the platform currently holds KAN.ST.

Super investors & insiders

Institutions holding (13F)

No tracked institution reports a position in KAN.ST as of their last filing.

Insider activity (SEC Form 4)

No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.

Insider activity (SEC Form 4)

Recent trades on TradeandTell

No one on the platform has traded KAN.ST yet.